20240826-国海证券-恒瑞医药-600276.SH-2024年中报点评_创新药收入快速增长_出海成为第二引擎_5页_276kb

中文总结：

这份报告是对恒瑞医药2024年中报的分析点评。根据证券研究报告，恒瑞医药在2024上半年营业收入达到136亿元，同比增长218%；归属于上市公司股东的净利润为343亿元，同比增长487%；扣除非经常性损益后净利润为349亿元，同比增长556%。主要增长动力来自创新药收入的快速增长，2024年上半年其创新药收入达到661.2亿元，同比增长33%，出海业务成为第二增长引擎，对公司经营起到推动作用。

在创新方面，恒瑞医药积极推进临床试验，多项产品获批上市，包括富马酸泰吉利定、氟唑帕利和脯氨酸恒格列净等。公司在研管线也取得进展，研究报告预计2024-2026年公司营业收入将达到263亿元、301亿元、343亿元，归母净利润为56亿元、65亿元、77亿元，对应PE分别为50、42、36倍。

同时，报告提示了相关风险，包括产品销售不及预期、产品临床失败风险、核心技术变动风险、出海进度不及预期以及行业政策变动风险。研究人员维持“买入”评级，推荐关注恒瑞医药的创新药发展和国际化进程。

English Summary:

This report analyzes the Q2 FY2024 performance of Hengrui Pharmaceutical (600276). According to the research, the company achieved revenue of CNY 13.6 billion in Q2, representing a 218% YoY growth. Net profit attributable to shareholders was CNY 34.3 billion (-487% YoY growth), while non-recurring items adjusted net profit was CNY 34.9 billion (-556% YoY growth).

The main growth driver is the expanding market for innovative medicines, which contributed CNY 66.12 billion in revenue (YoY +33%), with overseas expansion serving as the second growth engine. Despite intensified competition, product price cuts, and market access challenges, growth in innovative drugs remains strong, partly supported by an upfront payment of EUR 160 million from Merck Healthcare.

The implementation of the 9th batch of national centralized drug procurement in March 2024 impacted revenue, particularly for products like caspofungin injection and iodofantrin injection. Additionally, clinical pipeline advances have led to new drug approvals including Fabrazole, Fozapasone, and Pegloticase. The report forecasts revenue and net profit growth with increasing innovation drug contributions, expecting a [buy] recommendation and positive outlook under the SECURITY VIEW outline.

Key Risks: Sales underperformance, clinical trial failures, core technology/management team changes, overseas progress slower than expected, and industry policy shifts.